SI3224376T1 - DNA nečistoče v sestavku, ki obsega parvovirusni virion - Google Patents

DNA nečistoče v sestavku, ki obsega parvovirusni virion

Info

Publication number
SI3224376T1
SI3224376T1 SI201530908T SI201530908T SI3224376T1 SI 3224376 T1 SI3224376 T1 SI 3224376T1 SI 201530908 T SI201530908 T SI 201530908T SI 201530908 T SI201530908 T SI 201530908T SI 3224376 T1 SI3224376 T1 SI 3224376T1
Authority
SI
Slovenia
Prior art keywords
composition
dna impurities
parvoviral virion
parvoviral
virion
Prior art date
Application number
SI201530908T
Other languages
English (en)
Other versions
SI3224376T2 (sl
Inventor
Jacek Lubelski
Wilhelmus Theodorus Johannes M. C. HERMENS
Original Assignee
Uniqure Ip B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000715&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3224376(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure Ip B.V. filed Critical Uniqure Ip B.V.
Publication of SI3224376T1 publication Critical patent/SI3224376T1/sl
Publication of SI3224376T2 publication Critical patent/SI3224376T2/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201530908T 2014-11-28 2015-11-27 DNA nečistoče v sestavku, ki obsega parvovirusni virion SI3224376T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195464 2014-11-28
EP15801422.5A EP3224376B2 (en) 2014-11-28 2015-11-27 Dna impurities in a composition comprising a parvoviral virion
PCT/EP2015/077882 WO2016083560A1 (en) 2014-11-28 2015-11-27 Dna impurities in a composition comprising a parvoviral virion

Publications (2)

Publication Number Publication Date
SI3224376T1 true SI3224376T1 (sl) 2020-01-31
SI3224376T2 SI3224376T2 (sl) 2023-07-31

Family

ID=52000715

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530908T SI3224376T2 (sl) 2014-11-28 2015-11-27 DNA nečistoče v sestavku, ki obsega parvovirusni virion

Country Status (19)

Country Link
US (2) US11021762B2 (sl)
EP (3) EP3591070B1 (sl)
JP (1) JP6741345B2 (sl)
KR (1) KR102528156B1 (sl)
CN (1) CN107208142B (sl)
AU (1) AU2015352469B2 (sl)
BR (1) BR112017011217A2 (sl)
CA (1) CA2968622A1 (sl)
CY (1) CY1122223T1 (sl)
DK (2) DK3591070T3 (sl)
EA (1) EA035747B1 (sl)
ES (1) ES2751919T5 (sl)
FI (1) FI3224376T4 (sl)
HK (1) HK1244849B (sl)
HU (1) HUE046643T2 (sl)
PL (1) PL3224376T5 (sl)
PT (1) PT3224376T (sl)
SI (1) SI3224376T2 (sl)
WO (1) WO2016083560A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
SG10202001102XA (en) 2014-11-14 2020-03-30 Voyager Therapeutics Inc Modulatory polynucleotides
AU2015352469B2 (en) 2014-11-28 2021-09-16 Uniqure Ip B.V. DNA impurities in a composition comprising a parvoviral virion
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
CN110214187B (zh) 2016-05-18 2024-01-30 沃雅戈治疗公司 调节性多核苷酸
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019211741A1 (en) 2018-05-02 2019-11-07 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
WO2022188797A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
WO2024057210A1 (en) 2022-09-13 2024-03-21 Augmedics Ltd. Augmented reality eyewear for image-guided medical intervention
CN117660534B (zh) * 2023-12-13 2024-05-07 广州派真生物技术有限公司 一种降低重组腺相关病毒中宿主细胞dna残留的辅助质粒及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0562047A4 (en) * 1990-12-06 1995-11-02 Affymax Tech Nv Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
WO2001025462A1 (en) 1999-10-01 2001-04-12 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
CN101018858A (zh) * 2004-06-01 2007-08-15 建新公司 防止aav载体聚集的组合物和方法
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
EP3023500B1 (en) 2006-06-21 2020-02-12 uniQure IP B.V. Insect cells for the production of aav vectors
EP2069480B1 (en) * 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PT2173888T (pt) 2007-07-26 2016-11-17 Uniqure Ip Bv Resumo
CA2715924C (en) 2008-02-19 2021-01-12 Andrew Christian BAKKER Optimisation of expression of parvoviral rep and cap proteins in insect cells
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2011112089A2 (en) 2010-03-11 2011-09-15 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Mutated rep encoding sequences for use in aav production
KR101334072B1 (ko) * 2010-11-25 2013-11-29 한국표준과학연구원 핵산 정량 방법 및 키트
CN103703146A (zh) 2011-07-19 2014-04-02 株式会社日立高新技术 核酸分析方法和核酸分析装置
FR2986239A1 (fr) 2012-01-31 2013-08-02 Univ Strasbourg Biomarqueur pour les maladies inflammatoires pulmonaires chroniques
KR101738438B1 (ko) * 2012-07-06 2017-05-22 다카라 바이오 가부시키가이샤 아데노-관련 바이러스 벡터의 생산세포
WO2014018080A1 (en) * 2012-07-24 2014-01-30 Natera, Inc. Highly multiplex pcr methods and compositions
RU2725813C2 (ru) * 2013-03-15 2020-07-06 Дзе Чилдрен’З Хоспитал Оф Филадельфия Векторы, содержащие спейсерные/филлер полинуклеотидные последовательности, и способы их применения
AU2015352469B2 (en) 2014-11-28 2021-09-16 Uniqure Ip B.V. DNA impurities in a composition comprising a parvoviral virion

Also Published As

Publication number Publication date
DK3224376T3 (da) 2019-09-30
EP3224376B2 (en) 2023-04-26
EP3591070A1 (en) 2020-01-08
SI3224376T2 (sl) 2023-07-31
CN107208142A (zh) 2017-09-26
AU2015352469A1 (en) 2017-06-01
KR20170081704A (ko) 2017-07-12
HUE046643T2 (hu) 2021-11-29
ES2751919T3 (es) 2020-04-02
CY1122223T1 (el) 2020-11-25
AU2015352469B2 (en) 2021-09-16
EP4219742A1 (en) 2023-08-02
BR112017011217A2 (pt) 2018-02-06
JP6741345B2 (ja) 2020-08-19
ES2751919T5 (es) 2023-10-04
US20170321290A1 (en) 2017-11-09
US20210332447A1 (en) 2021-10-28
PL3224376T5 (pl) 2023-08-21
EA035747B1 (ru) 2020-08-05
EP3591070B1 (en) 2022-12-21
EA201791184A1 (ru) 2017-09-29
PT3224376T (pt) 2019-10-25
PL3224376T3 (pl) 2020-03-31
EP3224376B1 (en) 2019-08-07
CN107208142B (zh) 2024-03-26
JP2017535278A (ja) 2017-11-30
HK1244849B (zh) 2020-04-09
DK3224376T4 (da) 2023-05-30
WO2016083560A1 (en) 2016-06-02
DK3591070T3 (da) 2023-01-30
EP3224376A1 (en) 2017-10-04
CA2968622A1 (en) 2016-06-02
US11021762B2 (en) 2021-06-01
KR102528156B1 (ko) 2023-05-03
FI3224376T4 (fi) 2023-08-31

Similar Documents

Publication Publication Date Title
HK1244849B (zh) 包含細小病毒病毒體的組合物中的dna雜質
IL247581A0 (en) Genome editing without nucleases
IL246951B (en) A composition containing multiple genomes with crispr capability
PL3102722T3 (pl) Frakcjonowanie genomu
GB201410668D0 (en) Improvements in or relating to stairlifts
IL252591A0 (en) Genomic architecture mapping
GB201418892D0 (en) DNA editing
SG11201704517SA (en) Ink composition
GB2534113B (en) Ink composition
GB201408467D0 (en) Inks
GB201509208D0 (en) Improvements relating to printing
GB201418353D0 (en) Improvements in or relating to organic material
GB2529132B (en) Improvements in or relating to stairlifts
GB2526621B (en) Improvements in or relating to stairlifts
GB201412505D0 (en) Improvements relating to marking
GB201400699D0 (en) Improvements in or relating to servewear
GB201403570D0 (en) Ink composition
GB201418307D0 (en) Improvements in or relating to stairlifts
SI2898888T1 (sl) Sestavek, ki obsega iota-karagenan, proti virusnemu konjunktivitisu
GB201514034D0 (en) Improvements in or relating to DNA recombination
GB201514005D0 (en) Improvements in or relating to DNA recombination
GB201508136D0 (en) Improvements in or relating to dna recombination
GB201400751D0 (en) Ink composition
GB201410947D0 (en) Improvements to print compositions and processes including the same
GB201407981D0 (en) Ink compositions